Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers

MLA

Yoshihiko Yano, et al. “Clinical Features of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Patients with Cancers.” Journal of Cancer Research and Clinical Oncology, vol. 147, Nov. 2020, pp. 1747–56. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....620b0750e6291e15deb284a4e3bbfa1d&authtype=sso&custid=ns315887.

APA

Yoshihiko Yano, Hiroki Hayashi, Arata Sakai, Yuuki Shiomi, Eiichiro Yasutomi, Yoshihide Ueda, Kazutoshi Tobimatsu, Yuzo Kodama, Yuri Hatazawa, Ryutaro Yoshida, Naoki Asaji, & Atsushi Yamamoto. (2020). Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers. Journal of Cancer Research and Clinical Oncology, 147, 1747–1756.

Chicago

Yoshihiko Yano, Hiroki Hayashi, Arata Sakai, Yuuki Shiomi, Eiichiro Yasutomi, Yoshihide Ueda, Kazutoshi Tobimatsu, et al. 2020. “Clinical Features of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Patients with Cancers.” Journal of Cancer Research and Clinical Oncology 147 (November): 1747–56. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....620b0750e6291e15deb284a4e3bbfa1d&authtype=sso&custid=ns315887.